Akash Bhanshali-Backed Pharma Company Receives Rs 4.92 Crore NPPA Demand Notice

Indian equity benchmark indices traded marginally higher on Friday, with the benchmark Nifty 50 index rising 0.17 per cent to 23,730.50 during the session. Despite the positive broader market sentiment, shares of Natco Pharma traded lower after the company received a demand notice from the National Pharmaceutical Pricing Authority (NPPA). On Friday, Natco Pharma share price declined 0.37 per cent to Rs 1,200.

NPPA Issues Demand Notice To Natco Pharma

Natco Pharma informed exchanges that it received a demand notice dated May 12, 2026, from the National Pharmaceutical Pricing Authority (NPPA), New Delhi.

According to the company, the demand notice was issued under Paragraph 15 of the Drugs Price Control Order, 2013 (DPCO), directing Natco Pharma to deposit an amount of around Rs 4.92 crore, including overcharge amount, penalty and interest.

The notice alleges overcharging related to two drugs covering the period between April 2023 and November 2023.

Shareholding Pattern

According to the March 2026 shareholding pattern, promoters held 49.41 per cent stake in Natco Pharma. Foreign Institutional Investors (FIIs) held 17.37 per cent stake, while Domestic Institutional Investors (DIIs) held 5.46 per cent stake in the company.

Ace Investor Akash Bhanshali held a 1.01 per cent stake in Natco Pharma as of March 2026. Public shareholding stood at 27.74 per cent.

About Natco Pharma

Natco Pharma is an Indian pharmaceutical company engaged in developing, manufacturing and marketing specialty medicines, oncology products and active pharmaceutical ingredients.

The company has presence across domestic and international markets including the U.S., Canada, Europe and emerging markets, with focus on complex generics and niche therapeutic products.

Share your views on Natco Pharma and the recent NPPA demand notice in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.